Company Dossier · Health Care
Vertex Pharmaceuticals
- S&P 500
- Nasdaq-100
- Russell 1000
What Vertex Pharmaceuticals is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $12.6 billion, up 10% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $3.80 billion, up 8.6% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.50 billion, up 43% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $2.02 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (August 3, 2026): sentiment 0.80 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.90 of 1.Palanor Discourse
- Guidance in the last 90 days: 1 outlook figure raised, 0 lowered, 3 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 13, 2026): 2 risk factors added, 28 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $2.0 million on the open market.SEC Form 4
- 1,767 institutional managers reported a position at June 30, 2026 (+68 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 72 (64 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →What Vertex Pharmaceuticals is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Mixed
Expanding ↔ Retrenching
Steady
- Capital spending70th pct
- Debt raised—
- Buybacks vs capex31st pct
- Hiring filings35th pct
- Deals and private raises49th pct
- Patent publications6th pct
Confident ↔ Hedging
Mixed
- Call sentiment81st pct
- Call confidence78th pct
- Guidance changes38th pct
- Risk factors added34th pct
- Insider open-market trades38th pct
- + Call sentiment
- + Call confidence
- − Guidance changes
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver40th pct
- Stress filings48th pct
Credit
How these are built →No bond term sheets or tagged debt on file for Vertex Pharmaceuticals yet.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name Vertex Pharmaceuticals, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralVertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets
insidermonkey.com · via Marketaux · Oct 3, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 21, 2026LobbyingLobbying report (CGCN GROUP, LLC)third_quarter 2026 · $0.1 million
- Oct 20, 20268-KDirector or officer changeItem 5.02
- Oct 20, 2026LobbyingLobbying report (MARSHALL & POPP, LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (MCLARTY INBOUND LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (AVENUE SOLUTIONS)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (TARPLIN, DOWNS & YOUNG, LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (ALSTON & BIRD LLP)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (STANTON PARK GROUP)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (ALB SOLUTIONS)third_quarter 2026 · $0.1 million
- Oct 20, 2026PatentPatent granted: CELL HOUSING DEVICEUS 12766094
- Sep 1, 20268-KDirector or officer changeItem 5.02
- Jul 7, 20268-KMaterial agreement signedItem 1.01
- Jul 7, 2026Patent
- Jun 23, 2026Patent
- Jun 23, 2026Patent
- Jun 16, 2026Patent
- May 13, 20268-KDirector or officer changeItem 5.02
- May 13, 20268-KShareholder vote resultsItem 5.07
- Apr 29, 20268-KDirector or officer changeItem 5.02
- Feb 13, 202610-KAnnual report (10-K)2 risk factors added, 28 removed
- Aug 4, 20258-KDirector or officer changeItem 5.02
- May 14, 20258-KShareholder vote resultsItem 5.07
- Feb 13, 202510-KAnnual report (10-K)2 risk factors added, 0 removed
- Feb 10, 20258-KDirector or officer changeItem 5.02
- Feb 15, 202410-KAnnual report (10-K)6 risk factors added, 4 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Regeneron Pharmaceuticals REGN | $15.5B | $3.8B | Jun 30, 2026 |
| Biogen BIIB | $9.9B | $2.4B | Mar 31, 2026 |
| Incyte INCY | $5.4B | — | Mar 31, 2026 |
| Gilead Sciences GILD | $30.5B | $12.9B | Jun 30, 2026 |
| Amgen AMGN | $38.1B | $10.2B | Jun 30, 2026 |
| Neurocrine Biosciences NBIX | $3.4B | $0.6B | Jun 30, 2026 |
| United Therapeutics UTHR | $3.1B | $1.1B | Jun 30, 2026 |
| Exelixis EXEL | $2.4B | $1.2B | Jul 3, 2026 |